Biofrontera AG: Biofrontera'sbusiness operations on track

Leverkusen (pta032/11.11.2015/13:00 UTC+1) Biofrontera AG (FSE/AIM:B8F), the biopharmaceutical company focusing on sun-induced skin cancer announces that in light of the well above average volatility of the Company's share price and increased trading volumes in recent days, that there have been no new operational developments or matters which have arisen in relation to the ongoing approval processes or other operational aspects of the Company.

Business development activities remain in accordance with previous announcements in our regular financial reports, ad hoc releases and the recently published securities prospectus.

This also applies to the US approval application for the skin-cancer drug Ameluz® in the treatment of actinic keratosis. In line with the Company's timetable, Biofrontera yesterday submitted the "120-day safety update" which also includes clinical and cosmetic follow-up results of our Phase III trial for field treatment. The clinical part of the Phase III study for the European approval process for the treatment of basal cell carcinomas is expected to be complete this month, with preliminary results currently expected to be available as planned before the end of the year.

Enquiries, please contact:

Biofrontera AG
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
press@biofrontera.com
http://www.biofrontera.com

IR Germany: Brainwell Asset Solutions
Jürgen Benker +49 (0) 152 08931514

Nomad and Broker: Shore Capital
Bidhi Bhoma / Toby Gibbs +44(0) 20 7408 4090

IR UK: Seton Services
Toni Vallen +44(0) 20 7603 6797

Financial PR: Gable Communications
John Bick / Justine James
+44(0) 20 7193 7463
+44 (0)7872 061007

Background:
Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.
http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor & public relations
Phone:	+49 (0) 214 87 63 2 0
E-Mail:	press@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE0006046113 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart